Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer

John T. Comerci, Abbie L. Fields, Carolyn D. Runowicz, Gary L. Goldberg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Hormone replacement therapy (HRT) provides relief of menopausal symptoms, reverses atrophic urogenital changes, prevents osteoporosis, and produces favorable lipoprotein effects. Continuous combined HRT using 2.5 mg of medroxyprogesterone was designed to increase patient compliance by eliminating withdrawal bleeding while at the same time retaining the beneficial effects of HRT. There are limited long-term data, however, regarding the safety of continuous combined HRT. Of concern are reports of endometrial carcinoma arising in women receiving continuous HRT with low- dose progestin. Eight cases of women who developed endometrial carcinoma while on this regimen are presented. The possible increased risk of endometrial cancer associated with this regimen may be related to inadequate progestin dose, prior use of unopposed estrogen, poor patient compliance, use of less effective progestins, less efficient reversal of hyperplasia, and the use of progestin continuously.

Original languageEnglish (US)
Pages (from-to)425-430
Number of pages6
JournalGynecologic Oncology
Volume64
Issue number3
DOIs
StatePublished - 1997

Fingerprint

Hormone Replacement Therapy
Endometrial Neoplasms
Progestins
Patient Compliance
Medroxyprogesterone
Lipoproteins
Osteoporosis
Hyperplasia
Estrogens
Hemorrhage
Safety

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. / Comerci, John T.; Fields, Abbie L.; Runowicz, Carolyn D.; Goldberg, Gary L.

In: Gynecologic Oncology, Vol. 64, No. 3, 1997, p. 425-430.

Research output: Contribution to journalArticle

Comerci, John T. ; Fields, Abbie L. ; Runowicz, Carolyn D. ; Goldberg, Gary L. / Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer. In: Gynecologic Oncology. 1997 ; Vol. 64, No. 3. pp. 425-430.
@article{ff62a0c940224734b3f0050b17b592d5,
title = "Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer",
abstract = "Hormone replacement therapy (HRT) provides relief of menopausal symptoms, reverses atrophic urogenital changes, prevents osteoporosis, and produces favorable lipoprotein effects. Continuous combined HRT using 2.5 mg of medroxyprogesterone was designed to increase patient compliance by eliminating withdrawal bleeding while at the same time retaining the beneficial effects of HRT. There are limited long-term data, however, regarding the safety of continuous combined HRT. Of concern are reports of endometrial carcinoma arising in women receiving continuous HRT with low- dose progestin. Eight cases of women who developed endometrial carcinoma while on this regimen are presented. The possible increased risk of endometrial cancer associated with this regimen may be related to inadequate progestin dose, prior use of unopposed estrogen, poor patient compliance, use of less effective progestins, less efficient reversal of hyperplasia, and the use of progestin continuously.",
author = "Comerci, {John T.} and Fields, {Abbie L.} and Runowicz, {Carolyn D.} and Goldberg, {Gary L.}",
year = "1997",
doi = "10.1006/gyno.1996.4559",
language = "English (US)",
volume = "64",
pages = "425--430",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer

AU - Comerci, John T.

AU - Fields, Abbie L.

AU - Runowicz, Carolyn D.

AU - Goldberg, Gary L.

PY - 1997

Y1 - 1997

N2 - Hormone replacement therapy (HRT) provides relief of menopausal symptoms, reverses atrophic urogenital changes, prevents osteoporosis, and produces favorable lipoprotein effects. Continuous combined HRT using 2.5 mg of medroxyprogesterone was designed to increase patient compliance by eliminating withdrawal bleeding while at the same time retaining the beneficial effects of HRT. There are limited long-term data, however, regarding the safety of continuous combined HRT. Of concern are reports of endometrial carcinoma arising in women receiving continuous HRT with low- dose progestin. Eight cases of women who developed endometrial carcinoma while on this regimen are presented. The possible increased risk of endometrial cancer associated with this regimen may be related to inadequate progestin dose, prior use of unopposed estrogen, poor patient compliance, use of less effective progestins, less efficient reversal of hyperplasia, and the use of progestin continuously.

AB - Hormone replacement therapy (HRT) provides relief of menopausal symptoms, reverses atrophic urogenital changes, prevents osteoporosis, and produces favorable lipoprotein effects. Continuous combined HRT using 2.5 mg of medroxyprogesterone was designed to increase patient compliance by eliminating withdrawal bleeding while at the same time retaining the beneficial effects of HRT. There are limited long-term data, however, regarding the safety of continuous combined HRT. Of concern are reports of endometrial carcinoma arising in women receiving continuous HRT with low- dose progestin. Eight cases of women who developed endometrial carcinoma while on this regimen are presented. The possible increased risk of endometrial cancer associated with this regimen may be related to inadequate progestin dose, prior use of unopposed estrogen, poor patient compliance, use of less effective progestins, less efficient reversal of hyperplasia, and the use of progestin continuously.

UR - http://www.scopus.com/inward/record.url?scp=0031104798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031104798&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.4559

DO - 10.1006/gyno.1996.4559

M3 - Article

C2 - 9062144

AN - SCOPUS:0031104798

VL - 64

SP - 425

EP - 430

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -